VisEn claimed that the new VivoTag 645 represents the company’s agent offering in the lower-red wavelengths, enabling optimised and integrated imaging applications in both in-vivo and in-vitro research areas.

The VivoTag 645 is specifically designed for efficient and robust labeling of biomolecules, and is optimised for broad in-vitro and in-vivo imaging performance, including system compatibility, superior brightness, biocompatibility and stability in biological environments.

VisEn said that the fluorescence wavelength is matched for biological imaging applications on in-vitro and in-vivo fluorescence systems, including advanced microscopes, high content imaging and flow cytometry systems.

Additionally, VivoTag 645 is also optimised for use with VisEn’s fluorescence tomography FMT imaging systems which also have expanded wavelength capabilities to enable quantitative imaging of up to four channels and four different biomarkers of interest in-vivo.

Kirtland Poss, president and CEO of VisEn Medical, said: “Our new VivoTag 645 represents an important evolution in our fluorescent imaging agent product line.

“This new label is designed to be well-suited for applications both in-vitro and in-vivo research and we look forward to working closely with our customers in continually advancing these integrated research areas.”